Keywords: Anti-hypertensives, Cancer risk, Lancet, Boehringer Ingelheim, Micardis, Telmisartan

US researchers find increased risk of cancer with commonly-used antihypertensive drugs, notably telmisartan, but Boehringer defends its Micardis

Article | 14 June 2010

Print This

A meta-analysis, published today in The Lancet Oncology by Ilki Sipahi from The University Hospitals Case Medical Center in Cleveland ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in